S
S. Fahn
Researcher at Columbia University
Publications - 13
Citations - 6156
S. Fahn is an academic researcher from Columbia University. The author has contributed to research in topics: Parkinson's disease & Levodopa. The author has an hindex of 11, co-authored 13 publications receiving 6044 citations. Previous affiliations of S. Fahn include University of Rochester & NewYork–Presbyterian Hospital.
Papers
More filters
Journal ArticleDOI
The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it
S. Fahn,Gerald Cohen +1 more
TL;DR: The evidence favoring the oxidant stress hypothesis is persuasive, but not yet fully established, and believes that this is the best hypothesis available at present.
Journal Article
Pramipexole vs Levodopa as initial treatment for Parkinson disease: A randomized controlled trial
Robert G. Holloway,Ira Shoulson,K. Kieburtz,Michael P. McDermott,Pierre N. Tariot,Cornelia Kamp,Denni Day,Aileen Shinaman,S. Fahn,Anthony E. Lang,Kenneth Marek,John Seibyl,W. Weiner,M. Welsh,R. Pahwa,S. Coe,L. Barclay,L. Sutherland,K. Hildebrand,J. Hubble,C. Weeks,P. LeWitt,J. Miyasaki,J. Duff,E. Sime,O. Suchowersky,Mark Stacy,M. Kurth,M. Brewer,M. Harrigan,D. S. Russell,B. Fussell,B. Ford,S. Dillon,J. Hammerstad,C. Stone,D. Riley,P. Rainey,David G. Standaert,M. Tennis,F. Wooten,E. Rost-ruffner,S. Factor,D. Brown,Joseph Jankovic,F. Atassi,Roger Kurlan,Irenita Gardiner,M. Panisset,D. Amyot,J. Hall,A. Rajput,Theresa Shirley,Robert L. Rodnitzky,J. Dobson,C. Shults,D. Fontaine,C. Waters,S. Schuman,R. Pfeiffer,Shirley A. Rast,B. Pfeiffer,Alicia Brocht,Cindy Casaceli,Susan Daigneault,Karen Hodgeman,K. Honsinger,C. O'Connell,Arthur Watts +68 more
TL;DR: Initial pramipexole treatment resulted in significantly less development of wearing off, dyskinesias, or on-off motor fluctuations compared with levodopa (51%) (hazard ratio, 0.45; 95% confidence interval [CI], 0.66), and the mean improvement in total UPDRS score from baseline to 23.5 months was greater in thelevodopa group than in the pramipingxole group (9.5 points; P<.001).
Journal Article
Effect of deprenyl on the progression of disability in early Parkinson's disease
Ira Shoulson,S. Fahn,David Oakes,C. Odoroff,Anthony E. Lang,J. W. Langston,P. LeWitt,W. Olanow,J. B. Penney,C. Tanner,W. Koller,Robert L. Rodnitzky,J. S. Fink,J. H. Growdon,G. Paulson,Roger Kurlan,Joseph H. Friedman,S. Gancher,J. Nutt +18 more
TL;DR: It is concluded from these preliminary results that the use of deprenyl (10 mg per day) delays the onset of disability associated with early, otherwise untreated cases of Parkinson's disease.
Journal ArticleDOI
Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa
John B. Penney,David Oakes,Ira Shoulson,S. Fahn,Anthony E. Lang,J. William Langston,Peter A. LeWitt,C. Warren Olanow,Caroline M. Tanner,Karl Kieburtz +9 more
TL;DR: It is concluded that prior treatment with deprenyl or tocopherol did not reduce the occurrence of subsequent levodopa‐associated adverse effects in this population of patients with Parkinson's disease.